<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086787</url>
  </required_header>
  <id_info>
    <org_study_id>WTR-ECG-5</org_study_id>
    <nct_id>NCT01086787</nct_id>
  </id_info>
  <brief_title>Paracrine Mechanisms of Bone Marrow Stem Cell Signalling in Chronic Heart Failure</brief_title>
  <acronym>BM-CHF</acronym>
  <official_title>Paracrine Mechanisms of Bone Marrow Stem Cell Signalling in Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that chronic heart failure is associated with a general stem
      cell dysfunction, which translates into reduced paracrine function of adult stem cells from
      patients with chronic heart failure as compared to patients with preserved systolic function.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Paracrine properties of bone marrow cells from patients with heart failure</measure>
    <time_frame>1 day</time_frame>
    <description>To compare the paracrine properties of bone marrow-derived stem cells harvested from patients suffering chronic heart failure vs healthy subjects. In particular, we aim to determine if the cytoprotective, pro-angiogenic and anti-fibrotic effects mediated by bone marrow stem cells of heart failure patients are similar to those from healthy patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To study preconditioning of different bone marrow stem cells with different cytokines</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study in detail the temporal and spatial expression of paracrine factors in bone marrow stem cells in vitro, and to study the differences between bone marrow stem cells from patients with and without chronic heart failure</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate potential molecular mechanisms involved</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To find mechanisms to enhance expansion of different bone marrow stem cells in vitro</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Non heart failure patients</arm_group_label>
    <description>Patients without heart failure undergoing open chest surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orthopedic patients</arm_group_label>
    <description>Patients without heart failure undergoing orthopedic surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart failure patients</arm_group_label>
    <description>Patients with heart failure undergoing open chest surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Patients undergoing surgery for either cardiac surgery or orthopedic surgery</description>
    <arm_group_label>Non heart failure patients</arm_group_label>
    <arm_group_label>Orthopedic patients</arm_group_label>
    <arm_group_label>Heart failure patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum, white cells, urine, bone marrow
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Man and woman, undergoing cardiothoracic surgery, older than 18 years of age, with and
        without preserved left ventricular ejection fraction (LVEF &lt;40% and &gt;40%). Controls are man
        and women, older than 18 years of age, scheduled for orthopaedic surgery without a history
        of cardiac disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For all participants:

          1. Before any study-specific procedures, the appropriate written informed consent must be
             obtained.

          2. Male and female older than 18 years of age.

             For the cardiac patients:

          3. Being accepted for cardiothoracic surgery with the use of open chest surgery

          4. A known left ventricular ejection fraction, either assessed by echocardiography, MUGA
             or MRI. If LVEF &lt;40% a subject will be assigned to the chronic heart failure group, if
             LVEF &gt;40% a subject will be assigned to the control group.

             For the non-cardiac patients:

          5. Accepted for orthopedic surgery (e.g. total hip replacement) at the department of
             orthopedic surgery.

        Exclusion Criteria:

          1. An unstable medical condition, defined as having been hospitalized for a non-cardiac
             condition within 4 weeks of screening, or otherwise unstable in the judgment of the
             investigator (e.g. at risk of complications or adverse events unrelated to study
             participation).

          2. Younger than 18 years of age.

          3. Clinical history of chronic kidney disease (at any point prior to registration).

          4. Any known hepatic disease.

          5. Recent (within 3 months) history of alcohol or illicit drug abuse disorder, based on
             self-report.

          6. Clinically significant abnormality in chemistry, hematology, or urinalysis parameters
             performed within the screening period.

          7. Participation in any investigational device or drug trial(s) or receiving
             investigational agent(s) within 30 days.

          8. Any condition (e.g. psychiatric illness, etc.) or situation that, in the
             investigator's opinion, could put the subject at significant risk, confound the study
             results, or interfere significantly with the subject's participation in the study.

          9. Legally incompetent adults, for which reason what so ever.

             For the non-cardiac patients:

         10. A known history of cardiovascular disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. T. Ruifrok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. A. de Boer, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>W. H. van Gilst, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. Gnecchi, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pavia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>L. Kleijn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>W. T. Ruifrok, MD</last_name>
    <phone>+31 50 361 61 61</phone>
    <phone_ext>10248</phone_ext>
    <email>w.t.ruifrok@thorax.umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>R. A. de Boer, MD, PhD</last_name>
    <phone>+31 50 361 61 61</phone>
    <phone_ext>15381</phone_ext>
    <email>r.a.de.boer@thorax.umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Heart, Blood and Lung , University of Pavia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M. Gnecchi, MD, PhD</last_name>
      <email>massimiliano.gnecchi@unipv.it</email>
    </contact>
    <investigator>
      <last_name>M. Gnecchi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>R. A. de Boer, MD, PhD</last_name>
      <phone>+31 50 631 61 61</phone>
      <phone_ext>15381</phone_ext>
      <email>r.a.de.boer@thorax.umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>W. T. Ruifrok, MD</last_name>
      <phone>+31 50 631 61 61</phone>
      <phone_ext>10248</phone_ext>
      <email>w.t.ruifrok@thorax.umcg.nl</email>
    </contact_backup>
    <investigator>
      <last_name>W. T. Ruifrok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.umcg.nl</url>
    <description>Official website of the UMCG</description>
  </link>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2010</study_first_submitted>
  <study_first_submitted_qc>March 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <last_update_submitted>June 10, 2010</last_update_submitted>
  <last_update_submitted_qc>June 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>R.A. de Boer, MD, PhD</name_title>
    <organization>University Medical Center Groningen</organization>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Bone marrow</keyword>
  <keyword>Bone marrow mononuclear cells</keyword>
  <keyword>Surgery</keyword>
  <keyword>Orthopedic surgery</keyword>
  <keyword>Cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

